DK1035865T3 - HIV-1-Tat eller derivater deraf til profylaktisk og terapeutisk vaccination - Google Patents

HIV-1-Tat eller derivater deraf til profylaktisk og terapeutisk vaccination

Info

Publication number
DK1035865T3
DK1035865T3 DK98966601T DK98966601T DK1035865T3 DK 1035865 T3 DK1035865 T3 DK 1035865T3 DK 98966601 T DK98966601 T DK 98966601T DK 98966601 T DK98966601 T DK 98966601T DK 1035865 T3 DK1035865 T3 DK 1035865T3
Authority
DK
Denmark
Prior art keywords
tat
hiv
prophylactic
derivatives
therapeutic vaccination
Prior art date
Application number
DK98966601T
Other languages
English (en)
Inventor
Barbara Ensoli
Original Assignee
Ist Superiore Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita filed Critical Ist Superiore Sanita
Application granted granted Critical
Publication of DK1035865T3 publication Critical patent/DK1035865T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98966601T 1997-12-01 1998-11-30 HIV-1-Tat eller derivater deraf til profylaktisk og terapeutisk vaccination DK1035865T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97RM000743A IT1297090B1 (it) 1997-12-01 1997-12-01 Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
PCT/EP1998/007721 WO1999027958A2 (en) 1997-12-01 1998-11-30 Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination

Publications (1)

Publication Number Publication Date
DK1035865T3 true DK1035865T3 (da) 2008-02-04

Family

ID=11405378

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98966601T DK1035865T3 (da) 1997-12-01 1998-11-30 HIV-1-Tat eller derivater deraf til profylaktisk og terapeutisk vaccination

Country Status (23)

Country Link
US (2) US7744896B1 (da)
EP (2) EP1698347A3 (da)
JP (1) JP2001524531A (da)
CN (1) CN1283121A (da)
AP (1) AP2000001828A0 (da)
AT (1) ATE374041T1 (da)
AU (1) AU762893B2 (da)
BR (1) BR9814725A (da)
CA (1) CA2311647C (da)
CU (1) CU20000126A7 (da)
CY (1) CY1107818T1 (da)
DE (1) DE69838486T2 (da)
DK (1) DK1035865T3 (da)
EA (1) EA004330B1 (da)
ES (1) ES2293700T3 (da)
IL (1) IL136372A0 (da)
IT (1) IT1297090B1 (da)
NZ (1) NZ505373A (da)
OA (1) OA11419A (da)
PL (1) PL341818A1 (da)
PT (1) PT1035865E (da)
TR (1) TR200001553T2 (da)
WO (1) WO1999027958A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
US20010008627A1 (en) 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
WO2000078969A1 (en) * 1999-06-21 2000-12-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv tat peptides and multiple peptide conjugate system
KR100379577B1 (ko) * 2000-07-26 2003-04-08 최수영 세포침투성 티에이티 - 인간 글루탐산 탈수소효소 융합단백질, 이 융합단백질을 코딩하는 재조합폴리뉴클레오타이드, 이 융합단백질의 발현벡터 및 이융합단백질을 세포 내로 도입하는 방법
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
WO2003054006A2 (en) * 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
FR2834717B1 (fr) * 2002-01-11 2004-12-10 Bio Merieux Mutants de la proteine tat du virus vih-1
CA2483640A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
AU2003268688A1 (en) * 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Method of inducing immune responses
KR101159519B1 (ko) * 2002-11-19 2012-06-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｒｒｅ 및 ｃｔｅ를 포함하는 유전자 작제물 및 조성물 및이의 용도
WO2004047861A1 (en) * 2002-11-26 2004-06-10 Eurocine Ab Vaccines against viruses with cationic substances as adjuvants
AU2003297155B2 (en) 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
GB0323840D0 (en) * 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
EP1687017B1 (en) 2003-10-24 2013-03-06 Gencia Corporation Methods and compositions for delivering polynucleotides
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
AU2006249199A1 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
CA2660830A1 (en) 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
GB0802224D0 (en) * 2008-02-06 2008-03-12 Inst Superiore Di Sanito Process for the production of vaccine components
US9439922B2 (en) * 2008-05-14 2016-09-13 Jawaharlal Nehru Centre For Advanced Scientific Research Tat DNA sequences, gene constructs, vaccine and processes thereof
NZ595060A (en) 2009-03-23 2013-05-31 Pin Pharma Inc Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CN102153657A (zh) * 2011-01-18 2011-08-17 陕西师范大学 IL-24-Tat PTD融合蛋白及其构建方法和应用
GB201301119D0 (en) * 2013-01-22 2013-03-06 Vaxxit Srl Viral vaccines
EP2969006A4 (en) * 2013-03-14 2016-11-02 David Gladstone Inst COMPOSITIONS AND METHOD FOR TREATING IMMUNE WEAKAGE VIRUS INFECTION
JP2016533352A (ja) 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療
CN103936863B (zh) * 2014-04-23 2017-01-04 西安交通大学 一种调控stat3磷酸化的融合肽及其应用
CN104001155B (zh) * 2014-06-12 2016-04-13 中山大学 一种Tat蛋白及其制备方法和应用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
WO2018217897A1 (en) * 2017-05-23 2018-11-29 David Weiner Compositions and method for inducing an immune response
CN109943590B (zh) * 2019-04-18 2022-11-18 西南大学 一种复制缺陷型猪圆环病毒、其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83682B (en) * 1985-11-06 1988-12-05 Smithkline Beckman Corp Process for the expression of an aids virus gene
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
US6107062A (en) * 1992-07-30 2000-08-22 Inpax, Inc. Antisense viruses and antisense-ribozyme viruses
WO1994015634A1 (en) 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
CA2190972A1 (en) 1994-05-23 1995-11-30 Gideon Goldstein Compositions of transactivating proteins of human immunodeficiency virus
US6024965A (en) * 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
IT1297090B1 (it) 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
WO2001054719A2 (en) * 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Vaccine for the prophylactic or therapeutic immunization against hiv

Also Published As

Publication number Publication date
CU20000126A7 (es) 2005-10-19
WO1999027958A2 (en) 1999-06-10
OA11419A (en) 2004-04-21
JP2001524531A (ja) 2001-12-04
IL136372A0 (en) 2001-06-14
DE69838486D1 (de) 2007-11-08
US7744896B1 (en) 2010-06-29
CN1283121A (zh) 2001-02-07
EP1698347A2 (en) 2006-09-06
WO1999027958A9 (en) 1999-09-10
AU762893B2 (en) 2003-07-10
PT1035865E (pt) 2007-12-07
IT1297090B1 (it) 1999-08-03
DE69838486T2 (de) 2008-06-26
CY1107818T1 (el) 2013-06-19
US8197820B2 (en) 2012-06-12
ATE374041T1 (de) 2007-10-15
ITRM970743A1 (it) 1999-06-01
WO1999027958A3 (en) 1999-07-22
CA2311647C (en) 2013-03-19
AU2412699A (en) 1999-06-16
ES2293700T3 (es) 2008-03-16
CA2311647A1 (en) 1999-06-10
TR200001553T2 (tr) 2000-11-21
PL341818A1 (en) 2001-05-07
AP2000001828A0 (en) 2000-06-30
EP1035865A2 (en) 2000-09-20
EP1035865B1 (en) 2007-09-26
EA004330B1 (ru) 2004-04-29
EA200000596A1 (ru) 2000-12-25
EP1698347A3 (en) 2006-12-20
BR9814725A (pt) 2000-10-03
US20100015087A1 (en) 2010-01-21
NZ505373A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
DK1035865T3 (da) HIV-1-Tat eller derivater deraf til profylaktisk og terapeutisk vaccination
DK0909327T3 (da) Erythromyciner og fremgangsmåder til deres fremstilling
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
NO990965D0 (no) Terapeutiske fremgangsmÕter og blandinger som inneholder isoflavoner
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
DK0850948T3 (da) Propiophenonderivater og fremgangsmåde til fremstilling deraf
DK0811006T3 (da) Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse
DK1126876T3 (da) Adjuvanssystemer og vacciner
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
IS5525A (is) Innúðabúnaður og aðferð
NO985977D0 (no) Spiro-piperidinderivater og deres anvendelse som terapeutiske midler
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
NO971811D0 (no) Bicykliske tetrahydropyrazolopyridiner og deres anvendelse som legemidler
DK0765333T3 (da) Quillajasaponinadjuvans og vaccineformulering, der indeholder denne
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
NO993467D0 (no) Granuler som innbefatter klavulanat og en eller flere eksipienter
NO995513L (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-
NO985248L (no) Indolylpyrrolydenmetylpyrrolderivater og fremgangsmÕte for deres fremstilli
NO983472D0 (no) Taxoider, deres fremstilling og farmas°ytiske preparater inneholdende taxoidene
NO971505D0 (no) Trofinin og trofininhjelperproteiner
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO955242D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og deres terapeutiske anvendelse